Acurx Pharmaceuticals has been granted a new patent by the Japanese Patent Office for its DNA polymerase IIIC inhibitors, which target the treatment of MRSA, VRE, and Anthrax infections. This patent is set to expire in December 2039, subject to extension, and represents a significant advancement in the ongoing development of their pre-clinical antibiotic candidate, ACX-375C.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY85353) on May 13, 2025, and is solely responsible for the information contained therein.